Sitagliptin, a dipeptidyl peptidase-4 inhibitor, was selected as an active-comparator placebo proxy because it was recommended in clinical guidelines as a second-line glucose-lowering therapy, had a similar high cost to the study drugs, showed no effect on cardiovascular outcomes in a large randomized controlled trial and has been validated as a placebo proxy in prior claims-based research 20,41
Patient 1 and Patient 3 did not develop diabetes over the time of observation
So I have had, you know, Stu Phillips and Luke Van Loon, Brett Schoenfeld, we've talked about protein requirements, talking about getting the biggest bang for your buck with your training
"Products currently being marketed as 'GLP-1 patches' are not delivering GLP-1 medications like semaglutide or tirzepatide through the skin
Chronic weight management